A phase 1B/2 study to evaluate safety and anti-tumor activity of avelumab in combination with the poly (adenosine diphosphate [adp]-ribose) polymerase (parp) inhibitor talazoparib in patients with locally advanced or metastatic solid tumors
|Effective start/end date||11/1/17 → 11/30/22|
- PFIZER, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.